search
Back to results

Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections (CHLORHEX)

Primary Purpose

Infections and Respiratory Infectious

Status
Completed
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Chlorhexidine Gluconate
Placebo
Sponsored by
Assistance Publique Hopitaux De Marseille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infections and Respiratory Infectious

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult men and women over 18 years
  • Submitted to major pulmonary resections for primary lung cancer or pulmonary metastasis
  • Anatomical resections (segmentectomy, lobectomy, pneumonectomy)
  • With mediastinal lymph node dissection.
  • Patient fit for operation
  • After informed consent

Non inclusion criteria:

  • Patients < 18 years
  • Pulmonary infectious lesions
  • Recent respiratory infections
  • Tracheostomy
  • Swallow difficulties
  • Need for non-invasive ventilation before surgery
  • Documented sensibility to Chlorhexidine
  • Previous ENT cancer
  • Previous thoracic surgery
  • Patients with an oral assessment score (OAG) >9

Sites / Locations

  • Assistance Publique Hopitaux de Marseille

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

chlorhexidine gluconate

placebo

Arm Description

Outcomes

Primary Outcome Measures

proportion of patients requiring ventilatory support

Secondary Outcome Measures

occurrence of documented hospital-acquired respiratory infections
occurrence of documented non-respiratory hospital-acquired infections

Full Information

First Posted
June 5, 2012
Last Updated
August 6, 2015
Sponsor
Assistance Publique Hopitaux De Marseille
search

1. Study Identification

Unique Protocol Identification Number
NCT01613365
Brief Title
Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections
Acronym
CHLORHEX
Official Title
Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections: a Multicentric, Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
May 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Despite improvement of per and postoperative management, major pulmonary surgery continues to carry out a high morbidity with a significant mortality. Among postoperative complications, respiratory failures (nosocomial pneumonia, ARDS) are currently the most frequent and serious, as well as being the primary cause of hospital death, after major pulmonary resections. Vast majority of these complications are notoriously infectious and should be considered as hospital-acquired infections. These complications result in a dramatic increased of substantial hospital costs in term of length of hospital stay, antibiotics and morbidity. Current management of these complications stands on antibiotics, oxygen supply and physiotherapy. In severe case, a ventilatory support (invasive or non invasive) is justify in near 25 % of cases. Recent data have suggested that proximal airways colonizations could be an essential first step in the pathogenesis of theses respiratory failures. Previous works have long demonstrated that bacterial colonization was frequent between 21 to 40 % in lung cancer patients. These colonizations could act as a major predisposing factor to these postoperative respiratory failures. Because distal airways and lung parenchyma are free from bacteria at the moment of the surgery, respiratory complications should be the result from contamination by potential microorganisms belonging the upper aero-digestive tract. Consequently, decontamination of the oropharyngeal and nasopharyngeal cavities before and during the first days after surgery could have a beneficial advantage in the prevention of these complications. This decontamination has been demonstrated to be effective in critically-ill patients in intensive care unit, in cardiac surgery and in esophageal surgery. Decontamination of oropharynx and nasopharynx with Chlorhexidine Gluconate has significantly reduced the rate of postoperative global hospital-acquired infections and respiratory infectious as well. To date, data on the efficacy of this decontamination protocol in major pulmonary resections are not available.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infections and Respiratory Infectious

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
474 (Actual)

8. Arms, Groups, and Interventions

Arm Title
chlorhexidine gluconate
Arm Type
Experimental
Arm Title
placebo
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Chlorhexidine Gluconate
Intervention Description
Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Oropharyngeal and nasopharyngeal decontamination with placebo
Primary Outcome Measure Information:
Title
proportion of patients requiring ventilatory support
Time Frame
36 MONTHS
Secondary Outcome Measure Information:
Title
occurrence of documented hospital-acquired respiratory infections
Time Frame
36 MONTHS
Title
occurrence of documented non-respiratory hospital-acquired infections
Time Frame
36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult men and women over 18 years Submitted to major pulmonary resections for primary lung cancer or pulmonary metastasis Anatomical resections (segmentectomy, lobectomy, pneumonectomy) With mediastinal lymph node dissection. Patient fit for operation After informed consent Non inclusion criteria: Patients < 18 years Pulmonary infectious lesions Recent respiratory infections Tracheostomy Swallow difficulties Need for non-invasive ventilation before surgery Documented sensibility to Chlorhexidine Previous ENT cancer Previous thoracic surgery Patients with an oral assessment score (OAG) >9
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
BERNARD BELAIGUES
Organizational Affiliation
Assistance Publique hôpitaux de Marseille
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
D'JOURNO BENOIT
Organizational Affiliation
AP HM
Official's Role
Principal Investigator
Facility Information:
Facility Name
Assistance Publique Hopitaux de Marseille
City
Marseille
ZIP/Postal Code
13354
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
29671041
Citation
D'Journo XB, Falcoz PE, Alifano M, Le Rochais JP, D'Annoville T, Massard G, Regnard JF, Icard P, Marty-Ane C, Trousse D, Doddoli C, Orsini B, Edouard S, Million M, Lesavre N, Loundou A, Baumstarck K, Peyron F, Honore S, Dizier S, Charvet A, Leone M, Raoult D, Papazian L, Thomas PA. Oropharyngeal and nasopharyngeal decontamination with chlorhexidine gluconate in lung cancer surgery: a randomized clinical trial. Intensive Care Med. 2018 May;44(5):578-587. doi: 10.1007/s00134-018-5156-2. Epub 2018 Apr 18.
Results Reference
derived

Learn more about this trial

Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections

We'll reach out to this number within 24 hrs